The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial
Open accessAbstract
Background & aims Dietary restriction of fermentable carbohydrates (a low FODMAP diet) has been reported to reduce symptoms in some patients with irritable bowel syndrome (IBS). We performed a randomized, placebo-controlled study to determine its effects on symptoms and the fecal microbiota in patients with IBS.Methods We performed a 2×2 factorial trial of 104 patients with IBS (18-65 years old), based on the Rome III criteria, at 2 hospitals in the United Kingdom. Patients were randomly assigned (blinded) to groups given counselling to follow a sham diet or diet low in FODMAPs for 4 weeks, along with a placebo or multistrain probiotic formulation, resulting in 4 groups (27 receiving sham diet/placebo, 26 receiving sham diet/probiotic, 24 receiving low FODMAP diet /placebo, and 27 receiving low FODMAP diet/probiotic). The sham diet restricted a similar number of staple and non-staple foods as the low FODMAP diet; the diets had similar degrees of difficulty to follow. Dietary counselling was given to patients in all groups and data on foods eaten and compliance were collected. The incidence and severity of 15 gastrointestinal symptoms and overall symptoms were measured daily for 7 days before the study period; along with stool frequency and consistency. At baseline, global and individual symptoms were measured, along with generic and disease-specific health-related quality of life, using standard scoring systems. All data were collected again at 4 weeks, and patients answered questions about adequate symptom relief. Fecal samples were collected at baseline and after 4 weeks and analyzed by quantitative PCR and 16S rRNA sequencing. The co-primary endpoints were adequate relief of symptoms and stool Bifidobacterium species abundance at 4 weeks.Results There was no significant interaction between the interventions in adequate relief of symptoms (P = .52) or Bifidobacterium species (P = .68). In the intention-to-treat analysis, a higher proportion of patients in the low FODMAP diet had adequate symptom relief (57%) than in the sham diet group (38%), although the difference was not statistically significant (P = .051). In the per-protocol analysis, a significantly higher proportion of patients on the low FODMAP diet had adequate symptom relief (61%) than in the sham diet group (39%) (P = .042). Total mean IBS-Severity Scoring System score was significantly lower for patients on the low FODMAP diet (173 ± 95) than the sham diet (224 ± 89) (P = .001), but not different between those given probiotic (207 ± 98) or placebo (192 ± 93) (P = .721) Abundance of Bifidobacterium species was lower in fecal samples from patients on the low FODMAP diet (8.8 rRNA genes/g) than patients on the sham diet (9.2 rRNA genes/g) (P = .008), but higher in patients given probiotic (9.1 rRNA genes/g) than patients given placebo (8.8 rRNA genes/g) (P = .019). There was no effect of the low FODMAP diet on microbiota diversity in fecal samples.Conclusions In a placebo-controlled study of patients with IBS, a low FODMAP diet associates with adequate symptom relief and significantly reduced symptom scores compared with placebo. It is not clear whether changes resulted from collective FODMAP restriction or removal of a single component, such as lactose. Co-administration of the multistrain probiotic increased numbers of Bifidobacterium species, compared with placebo, and might be given to restore these bacteria to patients on a low FODMAP diet. Trial registration no: ISRCTN02275221.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the long term consequences of current dietary interventions with reported benefit in IBS, such as supplementation with psyllium fiber and the low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet31, 32, on the gut microbiome remain to be seen.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diversity, stability and resilience of the human gut microbiota
Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K., & Knight, R. (2012) · Nature · doi:10.1038/nature11550 · Cited by 5,533
Richness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662
Validating the SF-36 health survey questionnaire: new outcome measure for primary care.
Brazier, J. E., Harper, R., Jones, N. M., O’Cathain, A., Thomas, K. J., Usherwood, T. P., & Westlake, L. (1992) · BMJ · doi:10.1136/bmj.305.6846.160 · Cited by 4,660
Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV
Drossman, D. A. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.032 · Cited by 2,444
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome
Halmos, E. P., Power, V. A., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.09.046 · Cited by 1,249
An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota
Jeffery, I. B., O'Toole, P. W., Öhman, L., Claesson, M. J., Deane, J., Quigley, E. M. M., & Simrén, M. (2012) · Gut · doi:10.1136/gutjnl-2011-301501 · Cited by 835
The impact of irritable bowel syndrome on health-related quality of life
Gralnek, I. M., Hays, R. D., Kilbourne, A., Naliboff, B., & Mayer, E. A. (2000) · Gastroenterology · doi:10.1053/gast.2000.16484 · Cited by 781
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–430 of 430
Beyond Symptom Relief: A Review of Low-FODMAP Diet Implementation in Irritable Bowel Syndrome
Judijanto, L. (2025) · European Journal of Medical and Health Research · doi:10.59324/ejmhr.2025.3(6).22
Wang, Z., Chen, Y., Li, X., Li, L., Chen, B., Chen, M., & Zheng, H. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01845-w · Cited by 1
Naseri, K., Dabiri, H., Rostami-Nejad, M., Yadegar, A., Houri, H., Olfatifar, M., Sadeghi, A., Saadati, S., Ciacci, C., Iovino, P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14985032
Naseri, K., Dabiri, H., Rostami-Nejad, M., Yadegar, A., Houri, H., Olfatifar, M., Sadeghi, A., Saadati, S., Ciacci, C., Iovino, P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14985029
Xu, C., Song, Z., Hu, J.-Y., Li, C.-C., & Shen, H. (2024) · Figshare · doi:10.6084/m9.figshare.26719965
Naseri, K., Dabiri, H., Rostami-Nejad, M., Yadegar, A., Houri, H., Olfatifar, M., Sadeghi, A., Saadati, S., Ciacci, C., Iovino, P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14985035
Zhao, Y., Zhang, Y., Gao, Z., Yuan, X., & Li, X. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04621-y
Investigation of Nutrition Status in Patients with Irritable Bowel Syndrome
Altınok, E. İ., Aydın, E., Koval, S., Özbilgin, A. İ., Şener, B., Özcan, Ö. Ö., Çolak, H., Sarıyer, E. T., Çevik, E., & Karahan, M. Y. (2020) · DergiPark (Istanbul University)
Wilson, B. (2026) · Nutrition Today · doi:10.1097/nt.0000000000000795
Ahmed, N., Prajapati, H., Chauhan, M. R., Raval, V. H., Sehrawat, N., & Singh, N. A. (2025) · De Gruyter eBooks · doi:10.1515/9783112205150-007
Gut Health Restoration and Microbiome Repopulation in Individuals With Irritable Bowel Syndrome
Valk, R., & Valk, M. (2026) · Nutrition Today · doi:10.1097/nt.0000000000000798
Coss‐Adame, E., Cedillo, M. F. G., la Torre, M. F. H., & Arenas‐Martinez, J. S. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70631
Personalized gastroenterology: irritable bowel syndrome
Sen, K., Majumder, S., Islam, M. S., Das, S. K., & Madhu, N. R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40483-2.00009-1
Personalized nutrition plans based on gut microbiome analysis
Charles, M. R., & Charles, D. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40483-2.00033-9
Role du fructose dans la physiopathologie du syndrome de l'intestin irritable
Melchior, C. (2018) · theses.fr (ABES) · doi:10.70675/b07649edz908dz4d73za666z0112bc94cdf8
Kamphuis, J. B. J. (2019) · theses.fr (ABES) · doi:10.70675/e4003e6fzeffaz48a2z95a6zba874fe5eb4c
Low-FODMAP diet in the management of irritable bowel syndrome
Kaymak, M. Ş., & Ekici, E. M. (2026) · Nutrition & Food Science · doi:10.1108/nfs-12-2025-0440
Anderson, J. L., Ljótsson, B., Yao, C. K., Murray, H. B., & Biesiekierski, J. R. (2026) · Proceedings of The Nutrition Society · doi:10.1017/s002966512610305x
Hosseinian, S.-Z., Haghighatdoost, F., Hajihashemi, P., & Adibi, P. (2026) · Health Science Reports · doi:10.1002/hsr2.72662 · Cited by 1
The Challenges of Performing Controlled Trials of Diet Therapies in Gastroenterology
Day, A. S., Yao, C. K., Ford, A. C., Holtmann, G., & Halmos, E. P. (2026) · JGH Open · doi:10.1002/jgh3.70439
From Dysbiosis to systemic health: Microbiome modulation as a unified therapeutic framework
Dhiman, N. K., & Ahmad, S. R. (2026) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2026.03015
Manai, F., & Amadio, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1900029
Gribchenko, I. B., Korel, A., Glushchenko, E. E., Tryakhov, D. E., Aripova, F. K., Drannikov, A. A., & Bets, V. D. (2026) · Dairy · doi:10.3390/dairy7050087
Cao, B., Zhou, L., Hu, S., & Huang, Y. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1948754
Siedentopp, U. (2026) · Chinesische Medizin / Chinese Medicine · doi:10.1007/s00052-026-00202-0
Chapman, K., & Ballal, S. A. (2026) · Global Advances in Integrative Medicine and Health · doi:10.1177/27536130261490586
Fehlman, J., Peng, W., Pfenning, C., McCorkle, H., Nee, J. W., Chey, W. D., Rooker, C. T., Ballou, S., Lee, A. A., & Singh, P. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2026.1930300
Nie, C., Yuan, X., Liu, H., Ma, Q., Tian, B., Li, J., Zhang, M., 陈芝飞, & 李巨秀 (2026) · Foods · doi:10.3390/foods15213806
Gorini, F., Tonacci, A., Gabriele, M., & Borghini, A. (2026) · Nutrients · doi:10.3390/nu18213535
Metadata
- Authors
- Staudacher, H. M., Lomer, M. C. E., Farquharson, F. M., Louis, P., Fava, F., Franciosi, E., Scholz, M., Tuohy, K. M., Lindsay, J. O., Irving, P. M., & Whelan, K.
- Affiliations
- King's College London (GB)
- University of Aberdeen (GB)
- Fondazione Edmund Mach (IT)
- Queen Mary University of London (GB)
- Corresponding author
- Whelan, Kevin
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 153
- Issue
- 4
- Pages
- 936-947
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2625582958
- Cited by
- 430
- References
- 40
- Citations by year
- 2026: 27 · 2025: 37 · 2024: 40 · 2023: 28 · 2022: 54 · 2021: 69 · 2020: 53 · 2019: 58 · 2018: 53 · 2017: 11
- FWCI
- 50.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
- Own your potential (DEAKIN) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Portal (King's College London) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (Fondazione Edmund Mach) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion, cc-by-nc-nd)
- Funders
- Rural and Environment Science and Analytical Services Division
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- irritable bowel syndrome, low FODMAP diet, probiotics, Bifidobacterium, gut microbiota, dietary restriction, gastrointestinal symptoms, symptom relief, health-related quality of life, nutrition counseling, stool consistency, stool frequency, Rome III criteria, 16S rRNA gene sequencing, real-time PCR, dietary adherence
- MeSH terms
- Gastrointestinal Microbiome, Adult, Bifidobacterium, Combined Modality Therapy, Dietary Carbohydrates, Feces, Female, Fermentation, Humans, Intestines, London, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Remission Induction, Severity of Illness Index, Time Factors, Treatment Outcome, Probiotics, Ribotyping, Irritable Bowel Syndrome, Diet, Carbohydrate-Restricted, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review